Amicus Therapeutics, Inc.
FOLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,430,731 | $1,764,680 | $2,510,742 | $2,867,264 |
| - Cash | $190,553 | $158,702 | $181,657 | $213,752 |
| + Debt | $442,821 | $443,315 | $443,466 | $443,644 |
| Enterprise Value | $2,682,999 | $2,049,293 | $2,772,551 | $3,097,156 |
| Revenue | $169,061 | $154,688 | $125,249 | $149,706 |
| % Growth | 9.3% | 23.5% | -16.3% | – |
| Gross Profit | $147,720 | $139,471 | $113,551 | $134,870 |
| % Margin | 87.4% | 90.2% | 90.7% | 90.1% |
| EBITDA | $47,859 | -$5,764 | -$4,753 | $21,933 |
| % Margin | 28.3% | -3.7% | -3.8% | 14.7% |
| Net Income | $17,306 | -$24,420 | -$21,686 | $14,739 |
| % Margin | 10.2% | -15.8% | -17.3% | 9.8% |
| EPS Diluted | 0.056 | -0.08 | -0.07 | 0.049 |
| % Growth | 169.8% | -14.3% | -242% | – |
| Operating Cash Flow | $35,660 | -$26,526 | $7,758 | -$3,916 |
| Capital Expenditures | -$382 | -$2,403 | -$212 | -$288 |
| Free Cash Flow | $35,278 | -$28,929 | $7,546 | -$4,204 |